Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

Bellerophon Therapeutics logo

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

Advanced Chart

Key Stats

Today's Range
$0.0120
$0.0126
50-Day Range
$0.01
$0.06
52-Week Range
$0.0116
$0.0190
Volume
7,027 shs
Average Volume
18,907 shs
Market Capitalization
$146.80 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Stock News Headlines

Bellerophon Therapeutics Inc. (BLPH) Charts
Something very strange is happening...
What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone noticed when the U.S. Senate granted sweeping powers to a Harvard economist who has some dangerous ideas about the U.S. dollar. Now, he's issued a blueprint for what a coming "Mar-a-Lago Accord" could look like. One analyst who predicted the 2008 crisis says this plan could see the dollar fall in value by 40% in months and become a national nightmare.
Bellerophon Therapeutics, Inc. (BLPH)
Bellerophon Therapeutics Inc (BLPH)
Bellerophon Therapeutics Inc BLPH
See More Headlines

BLPH Stock Analysis - Frequently Asked Questions

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter.

Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020.The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), iBio (IBIO) and Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2023
Today
7/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.64 million
Price / Cash Flow
N/A
Book Value
$0.27 per share
Price / Book
0.04

Miscellaneous

Free Float
11,597,000
Market Cap
$146.80 thousand
Optionable
No Data
Beta
0.74

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:BLPH) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners